Chen Yating, Liu Xiaochen, Qiu Yuyao, Guo Qian, Zhang Feiyu, Nie Shaoping, Liu Hongtao, Long Deyong, Wang Xiao
Center for Coronary Artery Disease, Division of Cardiology, Beijing Anzhen Hospital, Capital Medical University, No. 2, Anzhen Road, Chao Yang District, Beijing, 100029, China.
Department of Cardiology, Shenzhen Longhua District Central Hospital, The Affiliated Central Hospital of Shenzhen Longhua District, Guangdong Medical University, Shenzhen, China.
BMC Cardiovasc Disord. 2025 Jul 19;25(1):531. doi: 10.1186/s12872-025-05005-y.
The effectiveness and safety of preventive percutaneous coronary intervention (PCI) on non-flow limiting vulnerable coronary plaque remain uncertain.
The aim of this meta-analysis was to evaluate the impact of preventive PCI plus optimal medical therapy (OMT) in non-flow limiting vulnerable plaque on clinical outcomes compared with OMT alone.
We searched PubMed, Embase, Web of Science (WOS), and the Cochrane from inception date to October 2024 for relevant studies which compared OMT and PCI plus OMT for non-flow limiting vulnerable plaques. Of the included studies, vulnerable plaques were defined as angiographically intermediate and non-flow limiting plaques with one or more of the following characteristics such as thin-cap fibroatheromas (TCFA), high lipid content, large plaque burden or small luminal area, although specific criteria differed among studies. The primary outcome was major adverse cardiac event (MACE). Pooled risk ratios (RR) were calculated using random effects models and heterogeneity was evaluated with the I statistic.
We included 4 randomized clinical trials with 1,843 participants. The follow-up duration ranged from 6 to 25 months. Patients in PCI group had similar incidence of MACE compared with OMT group (RR = 0.38; 95% CI 0.10 to 1.45; P = 0.16). For individual components of MACE, there were no statistical differences in the incidence of all-cause death, myocardial infarction (RR = 0.55; 95% CI 0.05 to 6.51; P = 0.64; RR = 0.81; 95% CI 0.12 to 5.19; P = 0.82). However, compared with OMT group, PCI group experienced a reduction of clinically-driven revascularization and hospitalization for unstable or progressive angina (RR = 0.11; 95% CI: 0.03-0.40; P < 0.001; RR = 0.16; 95% CI: 0.05-0.56; P = 0.004).
In patients with non-flow limiting vulnerable plaques, preventive PCI plus OMT showed a similar incidence of MACE but a reduction in the incidence of clinically-driven revascularization and hospitalizations for unstable or progressive angina, compared with OMT alone.
预防性经皮冠状动脉介入治疗(PCI)对无血流限制的易损冠状动脉斑块的有效性和安全性仍不确定。
本荟萃分析的目的是评估与单纯最佳药物治疗(OMT)相比,预防性PCI联合OMT对无血流限制的易损斑块患者临床结局的影响。
我们检索了PubMed、Embase、科学网(WOS)和考克兰图书馆,从数据库创建至2024年10月,查找比较OMT与PCI联合OMT治疗无血流限制易损斑块的相关研究。在纳入的研究中,易损斑块在血管造影上被定义为中度且无血流限制的斑块,具有以下一种或多种特征,如薄帽纤维粥样斑块(TCFA)、高脂质含量、大斑块负荷或小管腔面积,尽管不同研究的具体标准有所不同。主要结局是主要不良心脏事件(MACE)。使用随机效应模型计算合并风险比(RR),并使用I统计量评估异质性。
我们纳入了4项随机临床试验,共1843名参与者。随访时间为6至25个月。PCI组患者的MACE发生率与OMT组相似(RR = 0.38;95%CI 0.10至1.45;P = 0.16)。对于MACE的各个组成部分,全因死亡、心肌梗死的发生率无统计学差异(RR = 0.55;95%CI 0.05至6.51;P = 0.64;RR = 0.81;95%CI 0.12至5.19;P = 0.82)。然而,与OMT组相比,PCI组临床驱动的血运重建以及因不稳定或进行性心绞痛住院的情况有所减少(RR = 0.11;95%CI:0.03 - 0.40;P < 0.001;RR = 0.16;95%CI:0.05 - 0.56;P = 0.004)。
在无血流限制的易损斑块患者中,与单纯OMT相比,预防性PCI联合OMT的MACE发生率相似,但临床驱动的血运重建以及因不稳定或进行性心绞痛住院的发生率有所降低。